Wang Hansen, Williams Declan, Griffin Jennifer, Saito Takashi, Saido Takaomi C, Fraser Paul E, Rogaeva Ekaterina, Schmitt-Ulms Gerold
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Hirosawa, Wako-shi, Saitama, Japan.
PLoS One. 2017 Aug 23;12(8):e0182844. doi: 10.1371/journal.pone.0182844. eCollection 2017.
Alzheimer disease (AD) stands out amongst highly prevalent diseases because there is no effective treatment nor can the disease be reliably diagnosed at an early stage. A hallmark of AD is the accumulation of aggregation-prone amyloid β peptides (Aβ), the main constituent of amyloid plaques. To identify Aβ-dependent changes to the global proteome we used the recently introduced APPNL-F mouse model of AD, which faithfully recapitulates the Aβ pathology of the disease, and a workflow that interrogated the brain proteome of these mice by quantitative mass spectrometry at three different ages. The elevated Aβ burden in these mice was observed to cause almost no changes to steady-state protein levels of the most abundant >2,500 brain proteins, including 12 proteins encoded by well-confirmed AD risk loci. The notable exception was a striking reduction in immunoglobulin heavy mu chain (IGHM) protein levels in homozygote APPNL-F/NL-F mice, relative to APPNL-F/wt littermates. Follow-up experiments revealed that IGHM levels generally increase with age in this model. Although discovered with brain samples, the relative IGHM depletion in APPNL-F/NL-F mice was validated to manifest systemically in the blood, and did not extend to other blood proteins, including immunoglobulin G. Results presented are consistent with a cause-effect relationship between the excessive accumulation of Aβ and the selective depletion of IGHM levels, which may be of relevance for understanding the etiology of the disease and ongoing efforts to devise blood-based AD diagnostics.
阿尔茨海默病(AD)在高发性疾病中格外突出,因为目前尚无有效治疗方法,且该病在早期也无法得到可靠诊断。AD的一个标志是易于聚集的淀粉样β肽(Aβ)的积累,Aβ是淀粉样斑块的主要成分。为了确定Aβ依赖的全蛋白质组变化,我们使用了最近引入的AD小鼠模型APPNL-F,该模型忠实地再现了疾病的Aβ病理,以及一种通过定量质谱在三个不同年龄对这些小鼠的脑蛋白质组进行检测的工作流程。我们观察到,这些小鼠中升高的Aβ负担几乎没有导致最丰富的>2500种脑蛋白的稳态蛋白水平发生变化,包括12种由已充分证实的AD风险基因座编码的蛋白。一个显著的例外是,相对于APPNL-F/wt同窝小鼠,纯合子APPNL-F/NL-F小鼠的免疫球蛋白重链μ(IGHM)蛋白水平显著降低。后续实验表明,在该模型中IGHM水平通常会随着年龄的增长而增加。尽管是在脑样本中发现的,但APPNL-F/NL-F小鼠中相对的IGHM消耗在血液中也得到了全身性验证,并且没有扩展到其他血液蛋白,包括免疫球蛋白G。所呈现的结果与Aβ的过度积累和IGHM水平的选择性消耗之间的因果关系一致,这可能与理解该疾病的病因以及目前设计基于血液的AD诊断方法的努力相关。